Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLRB NYSE:IBIO NASDAQ:NRSN NASDAQ:SHPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLRBCellectar Biosciences$4.21-1.9%$5.01$4.11▼$66.00$13.69M0.59116,761 shs70,055 shsIBIOiBio$1.11+24.3%$0.83$0.56▼$6.89$22.48M0.891.66 million shs62.48 million shsNRSNNeuroSense Therapeutics$1.25-0.4%$1.19$0.80▼$2.60$17.08M1.61227,625 shs479,278 shsSHPHShuttle Pharmaceuticals$3.47-5.7%$3.74$3.00▼$56.25$3.94M-1.01264,317 shs877,984 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLRBCellectar Biosciences-4.67%-12.27%-17.50%-17.50%-93.16%IBIOiBio+5.06%+10.44%+3.93%+21.40%-68.89%NRSNNeuroSense Therapeutics+5.04%+2.46%+2.46%-35.17%+16.82%SHPHShuttle Pharmaceuticals+1.38%-3.16%-10.02%-5.15%-87.63%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLRBCellectar Biosciences$4.21-1.9%$5.01$4.11▼$66.00$13.69M0.59116,761 shs70,055 shsIBIOiBio$1.11+24.3%$0.83$0.56▼$6.89$22.48M0.891.66 million shs62.48 million shsNRSNNeuroSense Therapeutics$1.25-0.4%$1.19$0.80▼$2.60$17.08M1.61227,625 shs479,278 shsSHPHShuttle Pharmaceuticals$3.47-5.7%$3.74$3.00▼$56.25$3.94M-1.01264,317 shs877,984 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLRBCellectar Biosciences-4.67%-12.27%-17.50%-17.50%-93.16%IBIOiBio+5.06%+10.44%+3.93%+21.40%-68.89%NRSNNeuroSense Therapeutics+5.04%+2.46%+2.46%-35.17%+16.82%SHPHShuttle Pharmaceuticals+1.38%-3.16%-10.02%-5.15%-87.63%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLRBCellectar Biosciences 2.20Hold$375.008,807.36% UpsideIBIOiBio 3.00Buy$4.00260.36% UpsideNRSNNeuroSense Therapeutics 2.67Moderate Buy$14.001,024.50% UpsideSHPHShuttle Pharmaceuticals 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest SHPH, NRSN, IBIO, and CLRB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/21/2025IBIOiBioOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$5.0010/17/2025IBIOiBioLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$2.0010/15/2025NRSNNeuroSense TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold10/14/2025NRSNNeuroSense TherapeuticsNoble FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy10/14/2025SHPHShuttle PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025CLRBCellectar BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025NRSNNeuroSense TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025CLRBCellectar BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025NRSNNeuroSense TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025SHPHShuttle PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E)8/15/2025NRSNNeuroSense TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.00(Data available from 10/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLRBCellectar BiosciencesN/AN/AN/AN/A$8.98 per shareN/AIBIOiBio$400K56.21N/AN/A$1.41 per share0.79NRSNNeuroSense TherapeuticsN/AN/AN/AN/A$0.19 per shareN/ASHPHShuttle PharmaceuticalsN/AN/AN/AN/A$4.35 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLRBCellectar Biosciences-$44.58M-$19.91N/AN/AN/AN/A-486.67%-150.57%11/17/2025 (Estimated)IBIOiBio-$24.91M-$1.74N/AN/AN/AN/A-73.15%-45.51%N/ANRSNNeuroSense Therapeutics-$10.21M-$0.54N/A∞N/AN/AN/AN/A12/17/2025 (Estimated)SHPHShuttle Pharmaceuticals-$9.15M-$4.15N/A∞N/AN/A-772.76%-347.06%11/12/2025 (Estimated)Latest SHPH, NRSN, IBIO, and CLRB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/17/2025Q3 2025CLRBCellectar Biosciences-$1.91N/AN/AN/AN/AN/A8/14/2025Q2 2025CLRBCellectar Biosciences-$3.60-$3.39+$0.21-$3.39N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLRBCellectar BiosciencesN/AN/AN/AN/AN/AIBIOiBioN/AN/AN/AN/AN/ANRSNNeuroSense TherapeuticsN/AN/AN/AN/AN/ASHPHShuttle PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLRBCellectar BiosciencesN/A2.152.15IBIOiBio0.051.761.76NRSNNeuroSense TherapeuticsN/A0.71N/ASHPHShuttle PharmaceuticalsN/A3.073.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLRBCellectar Biosciences16.41%IBIOiBio7.90%NRSNNeuroSense Therapeutics1.04%SHPHShuttle Pharmaceuticals4.58%Insider OwnershipCompanyInsider OwnershipCLRBCellectar Biosciences5.04%IBIOiBio2.75%NRSNNeuroSense Therapeutics27.40%SHPHShuttle Pharmaceuticals12.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLRBCellectar Biosciences103.19 million3.03 millionOptionableIBIOiBio10020.26 million9.82 millionN/ANRSNNeuroSense Therapeutics10N/AN/ANot OptionableSHPHShuttle Pharmaceuticals51.07 million936,000Not OptionableSHPH, NRSN, IBIO, and CLRB HeadlinesRecent News About These CompaniesShuttle Pharmaceuticals stock surges on AI acquisition plans2 hours ago | in.investing.comShuttle Pharma Turns Radiation Into a Smart Weapon With Definitive LOI for Molecule.ai (NASDAQ:SHPH)4 hours ago | accessnewswire.comAShuttle Pharmaceuticals Acquires Molecule’s Assets for $10M5 hours ago | tipranks.comShuttle Pharmaceuticals to Acquire AI Molecular Modeling and Predictive Analytics PlatformOctober 21 at 4:05 PM | newsfilecorp.comNShuttle Pharmaceuticals (NASDAQ:SHPH) Earns "Sell (E+)" Rating from Weiss RatingsOctober 16, 2025 | americanbankingnews.comShuttle Pharmaceuticals announces extension of LOI with Molecule.aiOctober 10, 2025 | msn.comShuttle Executes LOI with Molecule.aiOctober 10, 2025 | globenewswire.comShuttle Pharmaceuticals stock soars after AI acquisition letter of intentOctober 10, 2025 | za.investing.comShuttle Pharmaceuticals to acquire Molecule.ai for $10MOctober 10, 2025 | msn.comShuttle to Enter $3.24 Billion AI Pharmaceutical MarketOctober 9, 2025 | globenewswire.comShuttle Pharmaceuticals Signs Consulting Agreement with IR AgencySeptember 22, 2025 | tipranks.comShuttle Pharmaceuticals Strengthens Board with New AppointmentsSeptember 18, 2025 | tipranks.comShuttle Pharmaceuticals Director Joseph Tung ResignsSeptember 17, 2025 | tipranks.comShuttle Pharmaceuticals Appoints Adam Chambers as DirectorSeptember 8, 2025 | tipranks.comShuttle Pharmaceuticals Director Steven Richards ResignsSeptember 5, 2025 | tipranks.comShuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Provides Second Quarter 2025 Corporate UpdateAugust 16, 2025 | finanznachrichten.deShuttle Pharma Provides Second Quarter 2025 Corporate UpdateAugust 14, 2025 | globenewswire.comShuttle Pharmaceuticals COO Resigns Amid Leadership ChangesJuly 30, 2025 | tipranks.comShuttle Pharmaceuticals Inc News (SHPH) - Investing.comJuly 2, 2025 | investing.comSHPH - Shuttle Pharmaceuticals Holdings Inc Key Metrics | MorningstarJune 28, 2025 | morningstar.comMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSHPH, NRSN, IBIO, and CLRB Company DescriptionsCellectar Biosciences NASDAQ:CLRB$4.21 -0.08 (-1.86%) Closing price 04:00 PM EasternExtended Trading$4.22 +0.01 (+0.36%) As of 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.iBio NYSE:IBIO$1.11 +0.22 (+24.30%) Closing price 04:00 PM EasternExtended Trading$1.12 +0.00 (+0.45%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.NeuroSense Therapeutics NASDAQ:NRSN$1.25 -0.01 (-0.40%) Closing price 03:59 PM EasternExtended Trading$1.28 +0.03 (+2.81%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.Shuttle Pharmaceuticals NASDAQ:SHPH$3.47 -0.21 (-5.71%) Closing price 04:00 PM EasternExtended Trading$4.05 +0.58 (+16.71%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys Will D-Wave's European Expansion Keep Fueling the Rally? Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
